Research on measurable signals of health and disease. Covers ultrasound imaging pipelines, fetal-distress detection, cancer monitoring, and fatigue biology.
Researchers have developed a method to use face masks to collect compounds in exhaled breath aerosols for analysis, enabling large-scale screening for disease biomarkers. The new technique uses a fiber inserted into an N95 face mask to concentrate molecules, allowing for more efficient identification through mass spectrometry.
Researchers identified an enzyme that breaks down mucus in the gut, providing a potential biomarker for intestinal diseases. The discovery could lead to earlier diagnosis and treatment of conditions such as ulcerative colitis and colorectal cancer.
A study analyzing dolphin blood biomarkers reveals age-related declines in hemoglobin, alkaline phosphatase, platelets, and lymphocytes. This variation in aging rates suggests potential strategies for slowing disease progression and preventing chronic conditions in humans.
Researchers identified five blood biomarkers associated with increased odds of clinical deterioration and death in COVID-19 patients. Elevated levels of these biomarkers were linked to inflammation and bleeding disorders, increasing the risk of ICU admission, ventilatory support, and mortality.
Researchers identified reduced functional connectivity between the cerebellum and extrastriate cortex in FMR1 premutation carriers, which may serve as an early emerging indicator of FXTAS. This biomarker could help predict who among FMR1 carriers will develop characteristic symptoms before they appear.
Scientists at UCL have discovered new biomarkers that can identify people with Type 1 diabetes who are likely to respond to the immunotherapy drug Abatacept. The study found that certain immune cells, known as 'follicular helper T cells', play a key role in the disease.
A UArizona-TGen led team identified robust biomarkers through proteomics and metabolomic analysis that could help guide treatment for tens of millions of patients who sustain traumatic brain injuries. The study found that RIC (Remote Ischemic Conditioning) can be an effective intervention in preventing severe long-term disabilities.
Researchers identified phosphoprotein biomarkers to guide cancer therapy, demonstrating a novel approach for identifying and detecting tumor drivers. The study's findings suggest that precision medicine is a realizable goal for rare and recalcitrant cancers.
A team of researchers has developed a multi-analyte test strip to monitor various biomarkers continuously, enabling personalized medicine. The technology combines big-data analysis with wearable sensors and minimally invasive methods.
A study compared the diagnostic accuracy of a blood biomarker tau phosphorylated at threonine 217 (P-tau217) with other biomarkers for distinguishing Alzheimer's from neurodegenerative diseases. The results showed that P-tau217 had high sensitivity and specificity, making it a promising tool for early diagnosis.
Researchers at UConn Health have developed a non-invasive biomarker panel for diagnosing and monitoring infant urinary tract obstruction. The panel of five proteins can detect UPJO in infants and toddlers, reducing the need for expensive and invasive tests.
The FDA has issued a positive response to C-Path's biomarker panel for detecting acute drug-induced skeletal muscle injury in phase 1 clinical trials. The panel, developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, uses four molecular biomarkers to aid in the detection of this condition.
Researchers at Duke University have developed a new optical sensing platform that can detect genomic cancer biomarkers in tissue samples using silver-plated gold nanostars. This technique has the potential to provide fast and reliable diagnostic results for cancer and other diseases, simplifying testing processes.
The Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium have developed a glutamate dehydrogenase (GLDH) biomarker to detect drug-induced liver injury in patients with inherited muscle disorders. The FDA has agreed to accept the Qualification Plan for GLDH as an important and accurate measurement of DILI.
A study of 9,029 adults found that cystatin C-based kidney function was associated with lower odds of frailty, falls, and cardiovascular disease events. The difference between cystatin C- and creatinine-based kidney function could be used to predict adverse outcomes in older adults.
Scientists at Flinders University recommend AIEgen technology for accurate clinical biomarkers and rapid disease screening through bioprobe tests. The technique can detect disease biomarkers in very low concentrations using low-cost, portable devices.
Researchers at Walter Reed Army Institute of Research have found that cathepsin B levels are increased in areas of injured brain relevant to critical executive functions. The study suggests that cathepsin B could be used as a blood-based biomarker to identify TBI severity within different brain regions and cerebral spinal fluid.
A nine-year longitudinal study found that family caregivers did not experience significantly greater inflammation levels compared to non-caregivers, challenging past research findings. The study suggests that caregiving may have minimal effects on physical health for most caregivers.
Two studies by European and US researchers found that higher consumption of these foods is associated with a lower risk of developing type 2 diabetes. Increasing fruit and vegetable intake by 66 grams per day was linked to a 25% lower risk, while whole grain consumption was also significantly related to reduced disease risk.
A new study found that a simple blood test can accurately predict concussion severity and duration, similar to expensive and invasive spinal taps. The test measures neurofilament light chain levels in the blood, which correlate strongly with the severity of concussions.
Researchers have discovered two novel biomarkers, FKBPL and CD44, that can predict key underlying causes of preeclampsia. The biomarkers show potential for early diagnosis in both early and late pregnancy, as well as targeted treatments.
Repeated blood tests measuring liver damage biomarker FIB-4 identify people at high risk of severe liver disease. The study found that increased FIB-4 scores between testing occasions can predict future liver cirrhosis, with almost half of affected individuals identifiable.
The study found that colchicine treatment was associated with reduced levels of inflammatory biomarkers and improved clinical outcomes in patients hospitalized with COVID-19. Colchicine's effectiveness in managing cardiac-related complications was also observed, suggesting potential benefits for these patients.
Researchers have identified unique metabolic signatures, called metabotypes, in over 50% of children with autism spectrum disorder. These biomarkers, detected through metabolomics tests, show promise in detecting early risk and potentially personalized therapies for ASD.
A study from University of Gothenburg found that COVID-19 patients with moderate to severe symptoms exhibited brain injury signs, including elevated GFAP and NfL biomarkers. These biomarkers were also associated with disease severity and ventilator treatment.
Researchers discovered a novel combination of biomarkers from baseline tumor tissues that predict improved clinical responses and prolonged survival in patients with advanced bladder cancer. ARID1A mutations and CXCL13 expression were associated with better overall survival, suggesting potential patient selection improvements.
Scientists at the University of Sussex have identified a potential pattern within blood that signals the presence of motor neuron disease. The discovery could significantly improve diagnosis with a future development of a blood test that identifies the unique biomarker, simplifying and speeding up diagnosis.
Researchers have developed a blood test that can accurately diagnose frontotemporal lobar degeneration (FTLD) and predict disease severity. The test measures neurofilament light chain levels in the blood, which are associated with FTLD progression, clinical phenotype, and prognosis.
Scientists at the University of Southampton are developing a rapid bedside test to diagnose neonatal Respiratory Distress Syndrome in premature babies. The test uses photonic technology and fingerprint spectroscopies, offering compact and versatile diagnostic capabilities.
A Cleveland Clinic-led research team will study the central vein sign as a reliable diagnostic marker for MS, aiming to improve accuracy and simplify clinical decision-making. The prospective study will enroll 400 patients at 11 centers in North America.
Researchers at A*STAR in Singapore have identified a potential biomarker, GSTT1, to screen the quality of donor's stem cells before harvesting. This biomarker can help determine the growth capacity and potency of MSCs, which is crucial for effective stem cell therapies.
Researchers identified 27 protein biomarkers in COVID-19 patients' blood plasma linked to disease severity. These molecular signatures can precisely classify patients according to World Health Organization's coding criteria, enabling early diagnosis and treatment.
A new mobile app assesses risk factors and key biomarkers from blood tests to produce a COVID-19 severity score. The tool has been validated using data from over 1,000 New York City patients, confirming its ability to identify those at high risk for severe cases.
A new study has found that neurofilament light chain (NfL) levels in the blood can distinguish individuals at high risk of Alzheimer's disease at age 22, on average 22 years before their estimated age of cognitive impairment.
A blood test using neurofilament light chain may predict recovery time after concussion, especially for those with multiple concussions. High levels of the biomarker are associated with severe symptoms like post-traumatic stress disorder and depression years later.
Two plasma and 10 cerebrospinal fluid biomarkers were identified to aid in early detection of MS with high sensitivity and specificity. These biomarkers may help monitor treatment response and disease progression.
Researchers found two single-miRNA and 29 two-miRNA biomarkers in serum plasma that can predict later onset of preeclampsia in asymptomatic pregnant women. Early identification could lead to prevention and better maternal and newborn outcomes.
Researchers at Duke University have developed a new imaging device that can measure the thickness and texture of the retina, potentially providing an early warning system for Alzheimer's disease. The device combines two technologies to spot structural changes in the retina, which could be indicative of the disease.
High DPP3 blood concentrations are linked to circulatory failure, cardiac depression, and acute kidney injury in burn patients. Decreasing DPP3 levels indicate a reduced risk of mortality.
Researchers at Duke University use plasmonics to boost fluorescence in diagnostics, increasing test brightness by over 150 times. The approach could make point-of-care diagnostics more widespread and affordable.
A study published in Brain found that a lag in blood drainage from the deep region of the brain is associated with ventriculomegaly and can be detected with MRI. The researchers identified this biomarker as a potential predictor for dementia and ventriculomegaly, which can be reversed by removing excess fluid.
A study published in Nature Communications reveals distinct urinary biomarker proteins for lupus nephritis in African American patients. The findings suggest that the ALCAM protein may be a promising therapeutic target. Researchers plan to conduct a longitudinal study to predict disease flares and improve treatment options.
Researchers identified IL-8 and IL-33 as key biomarkers for predicting pollen-specific nasal symptoms. These biomarkers also enable the prediction of symptom severity before the start of the pollen season.
Researchers have developed a graphene-based sensor that can detect biomarkers with high sensitivity, allowing for quick and simple disease diagnosis. The sensor uses the deformation of a single atomic sheet to trap biomarkers, which generates force deforming the graphene into a dome shape.
A new wearable smart patch is being developed to help people personalize their diets and reduce their risk of developing Type 2 diabetes. The device will measure key dietary biomarkers and send the information to an app, enabling users to precisely track how their bodies respond to different foods.
Scientists have identified biomarkers that signal potential heart damage from cancer treatment, allowing for early diagnosis and intervention. The findings could lead to better patient care and outcomes by enabling doctors to adjust chemotherapy types or dosages before cardiac damage occurs.
Researchers at CNIC discovered a biomarker, complement component 5 (C5), that detects atherosclerosis in its preclinical phase. Plasma levels of C5 can identify individuals with subclinical atherosclerosis, helping to select those who would benefit from more costly imaging analysis.
A new non-invasive method of monitoring diabetes uses saliva as a more convenient and sustainable alternative to traditional blood glucose testing. The research, published in PLOS ONE, achieved an accuracy rate of 95.2% using infrared platform technology.
Researchers investigated the association between preconception exposure to plastics and the risk of preterm birth. Higher concentrations of phthalates prior to conception were found to be associated with an increased risk of preterm birth in a recent study.
Researchers from Joslin Diabetes Center have identified a potential early biomarker for non-alcoholic fatty liver disease (NAFLD), which is linked to the regulation of liver fat metabolism and fibrosis. The protein NREP was found to decrease in levels as NAFLD progressed, suggesting its role as an early indicator of the disease.
Researchers discovered a biomarker for early detection of Alzheimer's disease in the form of high levels of RNA produced by the PHGDH gene. The study, published in Current Biology, suggests that overproduction of extracellular RNA by the PHGDH gene in elderly individuals may serve as an early warning sign of Alzheimer's disease.
A novel imaging marker has been developed to help diagnose and treat schizophrenia, using abnormal striatal function as a promising biomarker. The study, published in Nature Medicine, shows that this biomarker can distinguish between schizophrenia patients and healthy controls, while also predicting treatment response.
The OncoMX knowledgebase integrates cancer biomarker data with other relevant data types to facilitate efficient research and exploration. The platform combines heterogeneous data using the BioCompute Object framework, enabling users to compare various experimental data.
A recent study examined the association between sleep-disordered breathing and Alzheimer's disease biomarkers in older adults. The research revealed a significant link between the two conditions, with those with sleep-disordered breathing showing higher levels of biomarkers for Alzheimer's disease.
A team of scientists has developed a cancer diagnostics method that amplifies microRNA in live tumor cells using synthetic DNA and nanoparticles. This allows for the detection of tumor cells with high sensitivity, potentially leading to earlier diagnosis and improved treatment outcomes.
Researchers developed a computer program analyzing molecules in blood plasma to identify individuals at risk of becoming overweight and developing obesity-related diseases. The test is 90% accurate in detecting whether the subject will gain weight without intervention, also predicting diabetes and other health risks.
Monitoring lactate and bio-ADM levels helps identify high-risk sepsis patients. Bio-ADM measures blood vessel leakage, which can detect fatal outcomes despite low or decreasing lactate levels.
Researchers found that using AI to analyze CT scans can produce more accurate risk assessment for major cardiovascular events. Automated CT-based body composition biomarkers outperformed established clinical parameters like Framingham risk score and BMI in predicting adverse events.
A new blood test detects abnormal tau protein accumulation, differentiating healthy participants from those with Alzheimer's pathology and predicting disease progression. The test shows promise for early detection and diagnosis of Alzheimer's disease and related neurodegenerative disorders.
Scientists at UCF created functional nanomaterials for highly sensitive biomarker detection. The new method could enable high-performance technologies in various areas, including better diagnostic tools and test strip technology.